Scholarlink

<p>Hepatocellular carcinoma (HCC) remains a major global health challenge, largely because of its immunosuppressive “cold” tumor microenvironment (TME) that resists therapy. Interleukin-12 (IL-12) is a potent immune-activating cytokine, but its clinical application has constrained by severe systemic toxicity. Therefore, a delivery strategy that enables tumor-specific IL-12 expression is urgently needed. Here, a novel platform IL-12-cssDNA-LNP is developed using circular single-stranded DNA (cssDNA) encapsulated in lipid nanoparticles for controlled IL-12 delivery in HCC. The cssDNA demonstrates a clear expression advantage over plasmid DNA (pDNA) in HCC cells both in vitro and in vivo. Critically, our cssDNA-LNP platform is far less immunogenic and toxic than pDNA. In both subcutaneous and highly clinically relevant c-MYC/p53-driven primary HCC models, IL-12-cssDNA-LNP treatment significantly reprograms the “cold” TME and successfully suppresses tumor growth, and this is achieved without the severe off-target hepatic inflammation observed in the pDNA-treated group. The treatment also establishes durable immunological memory, conferring 100% protection against tumor rechallenge in cured mice. Our work establishes cssDNA-LNP as a versatile platform uncoupling high-efficiency hepatic gene expression from severe vector-driven toxicity. It is feasible to extend this novel gene delivery platform using cssDNA for HCC immunotherapy and other liver-associated diseases requiring precise and sustained gene delivery.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A low-toxicity circular single-stranded DNA platform for safe and potent IL-12 immunotherapy against hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Guang Hu,
  • Rui Ye,
  • Zhen Li,
  • Yijing Zhang,
  • Xisen Cao,
  • Rui Liu,
  • Beining Zhang,
  • Shuhan Yang,
  • Xiaoxiao Hu,
  • Jianming Wang,
  • Pengfei Zhang,
  • Jie Song

摘要

Hepatocellular carcinoma (HCC) remains a major global health challenge, largely because of its immunosuppressive “cold” tumor microenvironment (TME) that resists therapy. Interleukin-12 (IL-12) is a potent immune-activating cytokine, but its clinical application has constrained by severe systemic toxicity. Therefore, a delivery strategy that enables tumor-specific IL-12 expression is urgently needed. Here, a novel platform IL-12-cssDNA-LNP is developed using circular single-stranded DNA (cssDNA) encapsulated in lipid nanoparticles for controlled IL-12 delivery in HCC. The cssDNA demonstrates a clear expression advantage over plasmid DNA (pDNA) in HCC cells both in vitro and in vivo. Critically, our cssDNA-LNP platform is far less immunogenic and toxic than pDNA. In both subcutaneous and highly clinically relevant c-MYC/p53-driven primary HCC models, IL-12-cssDNA-LNP treatment significantly reprograms the “cold” TME and successfully suppresses tumor growth, and this is achieved without the severe off-target hepatic inflammation observed in the pDNA-treated group. The treatment also establishes durable immunological memory, conferring 100% protection against tumor rechallenge in cured mice. Our work establishes cssDNA-LNP as a versatile platform uncoupling high-efficiency hepatic gene expression from severe vector-driven toxicity. It is feasible to extend this novel gene delivery platform using cssDNA for HCC immunotherapy and other liver-associated diseases requiring precise and sustained gene delivery.

Graphical abstract